EX-99.1 2 exhibit_99-1.htm EXHIBIT 99.1
Exhibit 99.1
 
MeaTech Reports Financial Results for Q1 2022 and
Provides Business Update

The company continued to develop the technology, R&D and marketing
infrastructure necessary to accelerate toward commercialization of
 cultured meat
 
Rehovot, Israel, May 31, 2022 – MeaTech 3D Ltd. (Nasdaq: MITC) (“MeaTech”) today reported its financial results for Q1 2022 and provided a business update. MeaTech is an international group of deep-tech food companies at the forefront of the cultured meat industry. MeaTech Group uses science and technology to develop high-quality real meat products made from cells rather than farm-raised animals that are delicious, nutritious and safer than conventional meat.
 
Q1 2022 Financial Results Summary
 

 •
Research and development expenses totaled $2.1 million in the three months ending March 31, 2022, compared to $1.1 million in the same period in 2021. The 90% increase is mainly due to the addition of the company’s Belgian subsidiary and reflects MeaTech Group’s growing investment in research and development as it achieves its milestones and expands its cultured meat technology capabilities.
 

 •
General and administrative expenses totaled $2.1 million in the three months ending March 31, 2022, compared to $2.7 million in the same period in 2021. The 23% decrease is driven by lower share-based payment expenses, partially offset by higher D&O insurance expenses in the three months ending March 31, 2022.
 

 •
Marketing expenses totaled $1.1 million in the three months ending March 31, 2022, compared to $0.3 million in the same period in 2021. The 228% increase is mainly due to share-based payment expenses of $0.5 million, and the company’s growing investment in marketing activities.
 

 •
Operating loss totaled $5.3 million in the three months ending March 31, 2022, compared to $4.2 million in the same period in 2021. The 26% increase in the operating loss reflects the growing investment of MeaTech Group in research and development as well as marketing activities.
 


 •
Total comprehensive loss totaled $5.7 million in the three months ending March 31, 2022, or 40 cents per ordinary share ($4.00 per ADS), compared to $4.4 million, or 40 cents per ordinary share ($4.00 per ADS), in the same period in 2021.
 

 •
Cash flow used in operating activities totaled $2.8 million in the three months ending March 31, 2022, compared to $1.2 million in the same period in 2021, reflecting a 137% increase, driven mainly by increased research and development expenditures of the MeaTech Group.
 

 •
Cash flow used in investment activities totaled $1.0 million in the three months ending March 31, 2022, compared to $5.4 million in the same period in 2021, reflecting an 81% decrease. This resulted mainly from the $4.8 million cash component paid in the acquisition of Peace of Meat in Q1 2021.
 

 •
Cash flow from financing activities was $0.0 million in the three months ending March 31, 2022, compared to $29.2 million in the same period in 2021, during which the company completed its Nasdaq initial public offering.


•
Cash and cash equivalents were $15.3 million on March 31, 2022, compared to $19.2 million at year-end 2021, a decrease of 20%. The decrease was the result of the company’s ongoing operations.
 

 •
Current assets decreased by 23% to $16.9 million on March 31, 2022 from $22.1 million at year-end 2021 as a result of ongoing operations.
 

 •
Non-current assets increased by 25% to $23.2 million on March 31, 2022 from $18.5 million at year-end 2021, due mainly to a $4.1 million long-term lease asset of its new premises, offset by the recognition of a lease liability in the same amount in accordance with IFRS requirements.
 

 •
Total capital decreased 13% to $32.6 million on March 31, 2022, down from $37.6 million at year-end 2021. The decrease was mainly the result of ongoing operations.

Arik Kaufman, MeaTech’s Chief Executive Officer: "In just the first quarter of 2022, we have shown our rapid pace of progress toward commercialization. Our recent technological and scientific advancements and business activities have put us firmly on a path toward scaling our unique solution for the sustainable production of a wide variety of cultured meat products.”

Business highlights and developments during Q1 2022
 
•
Promising results with muscle stem cell differentiation: In February, MeaTech announced the successful development of a novel technology process in which muscle cells are fused into significant muscle fibers that better resemble those in whole cuts of meat. Bovine stem cells were isolated, proliferated in the lab, and differentiated into matured muscle cells with improved muscle fiber density, thickness and length. Based on these improvements, MeaTech has filed a provisional patent application with the USPTO.

•
New headquarters to widen R&D activity: In March, the company moved to new, more spacious headquarters with state-of-the-art laboratories in Rehovot, Israel, the epicenter of the country’s food-tech sector. The new space allows the company to enhance its cultured meat R&D and 3D bioprinting technology and continue growing the biology and engineering teams with a more expansive lab facility. The new headquarters also features a tasting kitchen.

•
Expansion of cultivated meat operation into the US to accelerate go-to-market strategy: In March 2022, MeaTech announced that it will be opening a US office. The new space will include activities in research and development, investor relations, and business development. MeaTech US will be another indication of the company’s rapid growth and scaling efforts.
 
•
Peace of Meat pilot plant and R&D facility in Belgium: In March, MeaTech announced that its wholly owned Belgian subsidiary, Peace of Meat, will build an R&D facility and pilot plant in Belgium, with construction expected to commence in 2022. The new facility will expand and accelerate MeaTech Group’s cultured avian technology and R&D capabilities and help propel the company’s market entry.
 
•
First-of-its-kind tasting event with Israeli anchor investors: In March, MeaTech hosted a
tasting event at the company’s headquarters with its Israeli anchor investors, including prominent food industry investors. Guests toured the labs and R&D facilities, observed the company’s 3D printing capabilities, and tasted hybrid chicken nuggets made with plant protein combined with cultured chicken developed by Peace of Meat.

•
Breakthrough in 3D bioprinting capabilities: In May, MeaTech announced the development of a unique, multi-nozzle 3D bioprinting system for industrial scale production of complex cultured meat products without impacting cell viability. The company plans to offer the technology to third parties via a wholly owned private MeaTech subsidiary as an additional revenue stream and to accelerate commercialization.

•
Strategic agreement between Peace of Meat and ENOUGH: In May, Peace of Meat signed a strategic agreement with ENOUGH, a leader in the field of mycoprotein, a fungi-based fermented food ingredient, to accelerate commercialization. This innovative initiative is expected to create game-changing hybrid alternative meat products that better resemble the flavor, aroma, texture, and even nutritional value of conventional meat.

•
MeaTech joins the United Nations Global Compact: In May, the company joined the UN Global Compact initiative, committing to ten universally accepted principles in the areas of human rights, labor, environment, and anti-corruption and to act in support of UN goals and issues embodied in the UN’s Sustainable Development Goals (SDGs).
 

Unaudited Condensed Consolidated Interim Information on the Financial Position

   
As of March 31
    
As of March 31
    
As of December 31
  
   
2022
    
2021
    
2021
  
   
USD thousands
    
USD thousands
    
USD thousands
  
Current assets
                  
                   
Cash and cash equivalents
    
15,257
      
35,971
      
19,176
  
Other investment
    
151
      
144
      
154
  
Receivables and prepaid expenses
    
1,513
      
391
      
2,782
  
Total current assets
    
16,921
      
36,506
      
22,112
  
                         
Non-current assets
                        
                         
Restricted deposits
    
415
      
50
      
405
  
Other investment
    
1,333
      
1,259
      
1,355
  
Right-of-use asset
    
4,050
      
294
      
407
  
Intangible assets
    
13,196
      
9,805
      
13,453
  
Fixed assets, net
    
4,183
      
1,797
      
2,922
  
                         
Total non-current assets
    
23,177
      
13,205
      
18,542
  
                         
Total Assets
    
40,098
      
49,711
      
40,654
  
                         
Current liabilities
                        
                         
Trade payables
    
746
      
1,357
      
382
  
Other payables
    
2,628
      
1,419
      
2,239
  
Current maturities of lease liabilities
    
488
      
207
      
165
  
                         
Total current liabilities
    
3,862
      
2,983
      
2,786
  
                         
Non-current liabilities
                        
                         
Long-term lease liabilities
    
3,595
      
96
      
246
  
                         
Total non-current liabilities
    
3,595
      
96
      
246
  
                         
Equity
                        
                         
Share capital and premium on shares
    
70,059
      
67,243
      
69,610
  
Capital reserves
    
4,026
      
2,004
      
3,708
  
Currency translation differences reserve
    
515
      
(8
)
    
1,275
  
Accumulated deficit
    
(41,959
)
    
(22,607
)
    
(36,971
)
                         
Total Equity
    
32,641
      
46,632
      
37,622
  
Total liabilities and Equity
    
40,098
      
49,711
      
40,654
  



Unaudited Condensed Consolidated Interim Information on Comprehensive Income

 
  
3-month
period ended
March 31,
    
3-month
period ended
March 31,
    
Year ended
December 31,
  
 
  
2022
    
2021
    
2021
  
 
  
USD thousands,
except share
data
    
USD thousands,
except share
data
    
USD thousands,
except share
data
  
 
                  
Research and development expenses
    
2,142
      
1,126
      
7,594
  
Marketing expenses
    
1,051
      
320
      
1,628
  
General and administrative expenses
    
2,118
      
2,760
      
8,010
  
 
                        
Operating loss
    
5,311
      
4,206
      
17,232
  
 
                        
Financing expenses (income), net
    
(323
)
    
(548
)
    
790
  
 
                        
Loss for the period
    
4,988
      
3,658
      
18,022
  
 
                        
Currency translation differences loss (income) that might be transferred to profit or loss over ILS
    
515
      
551
      
(1,942
)
Currency translation differences loss that might be transferred to profit or loss over EUR
    
245
      
237
      
1,447
  
 
                        
Total comprehensive loss for the period
    
5,748
      
4,446
      
17,527
  
 
                        
Loss per ordinary share, no par value (USD)
                        
 
                        
Basic and diluted loss per share (USD)
    
0.040
      
0.040
      
0.155
  
 
                        
Weighted-average number of shares outstanding - basic and diluted (shares)
    
126,235,376
      
90,346,518
      
115,954,501
  


Unaudited Condensed Consolidated Interim Information on Changes in Equity (Deficit)

 
  
Share and capital premium
    
Fair value of
financial assets
reserve
    
Transactions
with related
parties reserve
    
Currency
translation
differences
reserve
    
Share-based
payments
reserve
    
Accumulated deficit
    
Total
  
 
  
USD thousands
  
 
                                          
                                           
Balance as of January 1, 2022
    
69,610
      
(334
)
    
14
      
1,275
      
4,028
      
(36,971
)
    
37,622
  
 
                                                        
Share-based payments
    
-
      
-
      
-
      
-
      
714
      
-
      
714
  

                                                       
Exercise of options
    
449
                              
(396
)
            
53
  
Other comprehensive (loss)
    
-
      
-
      
-
      
(760
)
    
-
      
-
      
(760
)
Loss for the period
    
-
      
-
      
-
      
-
      
-
      
(4,988
)
    
(4,988
)
 
                                                        
Balance as of March 31, 2022
    
70,059
      
(334
)
    
14
      
515
      
4,346
      
(41,959
)
    
32,641
  
 
                                                        
Balance as of January 1, 2021
    
30,481
      
(334
)
    
14
      
780
      
3,639
      
(18,949
)
    
15,631
  
 
                                                        
Share-Based Payment
    
-
      
-
      
-
      
-
      
1,879
      
-
      
1,879
  
Issuance of shares and warrants, net
    
30,357
      
-
      
-
      
-
      
-
      
-
      
30,357
  
Exercise of options
    
6,405
                              
(3,194
)
            
3,211
  
Other comprehensive (loss)
            
-
      
-
      
(788
)
    
-
      
-
      
(788
)
Loss for the period
    
-
      
-
      
-
      
-
      
-
      
(3,658
)
    
(3,658
)
 
                                                        
Balance as of March 31, 2021
    
67,243
      
(334
)
    
14
      
(8
)
    
2,324
      
(22,607
)
    
46,632
  
 
                                                        
Balance as of January 1, 2021
    
30,481
      
(334
)
    
14
      
780
      
(3,639
)
    
(18,949
)
    
15,631
  
 
                                                        
Share-based payments
    
-
      
-
      
-
      
-
      
3,965
      
-
      
3,965
  
Issuance of shares and warrants, net
    
32,330
                                              
32,330
  
Exercise of options
    
6,799
      
-
      
-
      
-
      
(3,576
)
    
-
      
3,223
  
Other comprehensive income
   
-
      
-
      
-
      
495
      
-
      
-
      
495
  
Loss for the period
    
-
      
-
      
-
      
-
      
-
      
(18,022
)
    
(18,022
)
 
                                                        
Balance as of December 31, 2021
    
69,610
      
(334
)
    
14
      
1,275
      
4,028
      
(36,971
)
    
37,622
  


Unaudited Condensed Consolidated Interim Information on Cash Flows
 
  
Three months ended March 31,
2022
    
Three months ended March 31,
2021
    
Year ended
December 31,
2021
  
 
  
USD thousands
    
USD thousands
    
USD thousands
  
Cash flows – operating activities
                  
Net Loss for the period
    
(4,988
)
    
(3,658
)
    
(18,022
)
 
                        
Adjustments:
                        
Depreciation and amortization
    
382
      
109
      
680
  
Change in fair value of derivative
    
-
      
(304
)
    
(316
)
Change in fair value of other investment
    
(44
)
    
(74
)
    
(193
)
Changes in net foreign exchange expenses
    
(340
)
    
(174
)
    
1,279
  
Share-based payment expenses
    
714
      
1,879
      
3,965
  
 
                        
Changes in asset and liability items:
                        
Decrease (increase) in receivables and prepaid expenses
    
1,203
      
(50
)
    
(2,351
)
Increase (decrease) in trade payables
    
(382
)
    
736
      
(97
)
Increase in other payables
    
615
      
336
      
1,095
  
Net cash (used in) operating activities
    
(2,840
)
    
(1,200
)
    
(13,960
)
 
                        
Cash flows – investment activities
                        
Acquisition of fixed assets
    
(800
)
    
(219
)
    
(1,828
)
Increase of restricted deposit
    
(19
)
    
-
      
(337
)
Loan provided
    
-
      
(367
)
    
(367
)
Acquisition of subsidiary, net of cash acquired
    
(188
)
    
(4,848
)
    
(6,808
)
 
                        
Net cash used in investing activities
    
(1,007
)
    
(5,434
)
    
(9,340
)
 
                        
Cash flows – financing activities
                        
Proceeds from issuance of shares and warrants
    
-
      
29,281
      
29,281
  
Issuance costs
    
-
      
(3,283
)
    
(3,283
)
Repayment of liability for lease
    
(118
)
    
(58
)
    
(346
)
Proceeds on account of other investment
    
38
      
37
      
149
  
Proceeds from exercise of share options
    
53
      
3,211
      
3,222
  
 
                        
Net cash provided by (used in) financing activities
    
(27
)
    
29,188
      
29,023
  
 
                        
Increase (decrease) in cash and cash equivalents
    
(3,874
)
    
22,554
      
5,723
  
Effect of exchange differences on cash and cash equivalents
    
(45
)
    
(137
)
    
(103
)
Cash and cash equivalents at the beginning of the period:
    
19,176
      
13,556
      
13,556
  
 
                        
Cash and cash equivalents at end of period
    
15,257
      
35,973
      
19,176
  
 
                        
Non-cash activities
                        
Purchase of fixed assets
    
756
      
222
      
57
  
Issue of shares and options against intangible asset
    
-
      
4,359
      
6,332
  
 
About MeaTech
 
MeaTech is an international group of deep-tech food companies at the forefront of the cultured meat revolution. The company initiated activities in 2019 and is listed on the Nasdaq Capital Market under the ticker “MITC”. MeaTech maintains facilities in Rehovot, Israel and Antwerp, Belgium and is in the process of expanding activities to the US. The company believes cultivated meat technologies hold significant potential to improve meat production, simplify the meat supply chain, and offer consumers a range of new product offerings.
 
MeaTech aims to provide an alternative to industrialized animal farming that dramatically reduces carbon footprint, minimizes water and land usage, and prevents the slaughtering of animals. With a modular factory design, MeaTech aims to offer a sustainable solution for producing a variety of beef, chicken and pork products, both as raw materials and whole cuts.      
 
For more information, please visit: https://meatech3d.com
 
Forward-Looking Statements 
 
This press release contains forward-looking statements concerning MeaTech’s business, operations and financial performance and condition as well as plans, objectives, and expectations for MeaTech’s business operations and financial performance and condition. Any statements that are not historical facts may be deemed to be forward-looking statements. Forward-looking statements reflect MeaTech’s current views with respect to future events and are based on assumptions and subject to known and unknown risks and uncertainties, which change over time, and other factors that may cause MeaTech’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and are typically identified with words such as “may,” “could,” “should,” “will,” “would,” “believe,” “anticipate,” “estimate,” “expect,” “aim,” “intend,” “plan” or words or phases of similar meaning and include, without limitation, MeaTech’s expectations regarding the success of its cultured meat manufacturing technologies it is developing, which will require significant additional work before MeaTech can potentially launch commercial sales; MeaTech’s research and development activities associated with technologies for cultured meat manufacturing, including three-dimensional meat production, which involves a lengthy and complex process; MeaTech’s ability to obtain and enforce its intellectual property rights and to operate its business without infringing, misappropriating, or otherwise violating the intellectual property rights and proprietary technology of third parties; and other risks and uncertainties, including those identified in MeaTech’s Annual Report on Form 20-F for the fiscal year ended December 31, 2021, filed with the Securities and Exchange Commission on March 24, 2022. New risks and uncertainties may emerge from time to time, and it is not possible for MeaTech to predict their occurrence or how they will affect MeaTech. If one or more of the factors affecting MeaTech’s forward-looking information and statements proves incorrect, then MeaTech’s actual results, performance or achievements could differ materially from those expressed in, or implied by, forward-looking information and statements contained in this press release. Therefore, MeaTech cautions you not to place undue reliance on its forward-looking information and statements. MeaTech disclaims any duty to revise or update the forward-looking statements, whether written or oral, to reflect actual results or changes in the factors affecting the forward-looking statements, except as specifically required by law. 
 
MeaTech Press Contact: 
  
MeaTech Investor Contacts: 
  
  
Maissa Dauriac 
Rainier Communications 
mdauriac@rainierco.com 
 Tel: +1-818-642-5257 
Joseph Green 
Edison Group  
jgreen@edisongroup.com 
Tel: +1-646-653-7030  
Ehud Helft 
Edison Israel  
ehelft@edisongroup.com 
Tel: +1-212-378-8040